Victoza is a daily subcutaneous injection of liraglutide, a GLP-1 receptor agonist, FDA-approved for type 2 diabetes in adults and children 10 years and older. It lowers A1C by about 1.0 to 1.5 percent at the maximum 1.8 mg daily dose, produces 2 to 3 kilograms of weight loss, and — in the LEADER trial — reduced major adverse cardiovascular events by about 13 percent in adults with type 2 diabetes and established cardiovascular disease. This guide covers how Victoza works, dosing, efficacy, the LEADER cardiovascular trial, side effects, and how it fits alongside other diabetes medications.
What Victoza Is
Victoza is the brand name for liraglutide, a synthetic GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA in 2010. It is one of the longest-established injectable GLP-1 RAs and the only one approved for use in children with type 2 diabetes 10 years and older. The same molecule at a higher dose (3.0 mg daily) is marketed as Saxenda for chronic weight management.
How Victoza Lowers Blood Sugar
Liraglutide activates GLP-1 receptors throughout the body, producing four glucose-lowering effects:
- Glucose-dependent insulin release. The pancreas releases more insulin when blood glucose is elevated; less when normal. This minimizes hypoglycemia risk.
- Glucagon suppression. Reduces alpha-cell glucagon output during hyperglycemia, lowering hepatic glucose production.
- Slowed gastric emptying. Food leaves the stomach more gradually, blunting post-meal glucose peaks.
- Reduced appetite. Acts on hypothalamic and reward circuits to decrease hunger and food intake — contributing to weight loss and indirectly to glucose control.
Dosing Schedule for Type 2 Diabetes
| Week | Daily Dose | Purpose |
|---|---|---|
| Week 1 | 0.6 mg | Tolerance-building; not designed for full glycemic effect |
| Week 2 onward | 1.2 mg | First effective dose; assess A1C at 12 weeks |
| If A1C above target after 4+ weeks at 1.2 mg | 1.8 mg | Maximum diabetes dose |
Victoza is injected once daily, at any time of day, with or without food. The injection should be given at approximately the same time each day for consistent absorption.
Efficacy — A1C and Weight Loss
| Endpoint | Victoza 1.2 mg | Victoza 1.8 mg |
|---|---|---|
| A1C reduction | 0.8 to 1.2 percent | 1.0 to 1.5 percent |
| Fasting glucose reduction | about 28 to 38 mg/dL | about 35 to 45 mg/dL |
| Weight loss | 1 to 2 kg | 2 to 3 kg |
| Reached A1C below 7 percent | about 50 percent of users | about 55 to 65 percent of users |
The LEADER Cardiovascular Outcomes Trial
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), published in NEJM in 2016, enrolled 9,340 adults with type 2 diabetes and established CV disease or high CV risk. Patients were randomized to Victoza or placebo and followed for a median of 3.8 years.
| Outcome | Result on Victoza vs Placebo |
|---|---|
| Major adverse CV events (CV death, nonfatal MI, nonfatal stroke) | 13 percent relative risk reduction (HR 0.87) |
| Cardiovascular death | 22 percent relative risk reduction (HR 0.78) |
| All-cause mortality | 15 percent relative risk reduction (HR 0.85) |
| Nephropathy outcomes | 22 percent relative risk reduction (HR 0.78) |
| Severe hypoglycemia | Lower in liraglutide group |
LEADER established Victoza as the first GLP-1 RA with proven cardiovascular benefit and led directly to the FDA-approved indication for cardiovascular event reduction in adults with type 2 diabetes and established CV disease.
Side Effects of Victoza
| Side Effect | Frequency at 1.8 mg | Notes |
|---|---|---|
| Nausea | about 28 percent | Peaks in first 4 weeks; usually eases by week 8 |
| Diarrhea | about 17 percent | Usually mild; consider smaller meals |
| Vomiting | about 11 percent | Manageable with hydration and slow eating |
| Constipation | about 10 percent | Responds to fiber, fluids, gentle activity |
| Decreased appetite | about 11 percent | Often desired |
| Headache | about 9 percent | Usually transient |
| Injection site reactions | about 2 percent | Mild redness, itching, or small bumps |
| Hypoglycemia (with insulin/SU) | 10 to 25 percent | Reduce insulin or SU dose at start |
Serious but Uncommon Risks
- Acute pancreatitis. Rare. Severe persistent abdominal pain radiating to the back warrants urgent evaluation.
- Gallbladder disease. Cholelithiasis and cholecystitis can occur, particularly with rapid weight loss.
- Acute kidney injury. Usually from dehydration after severe vomiting or diarrhea.
- Hypersensitivity. Rare; rash, hives, angioedema.
- Thyroid C-cell tumors. Boxed warning based on rodent data. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.
Who Is a Good Candidate
- Adults with type 2 diabetes whose A1C is above target on diet, exercise, and metformin
- Adults with type 2 diabetes and established cardiovascular disease (LEADER indication)
- Children 10 years and older with type 2 diabetes inadequately controlled on metformin or insulin
- People who would benefit from modest weight loss alongside glucose control
- People who prefer daily routine over weekly injection scheduling
Who Should Not Use Victoza
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Type 1 diabetes (insulin remains primary)
- Diabetic ketoacidosis
- Severe gastroparesis
- Active or recurrent pancreatitis (clinician judgment)
- Pregnancy or planning pregnancy (discontinue before pregnancy)
Victoza vs Other Diabetes Drugs
| Drug | A1C Reduction | Weight Effect | CV Outcome Data | Cost |
|---|---|---|---|---|
| Metformin | 1.0 to 1.5 percent | Modest loss | UKPDS 34 benefit | Low |
| Victoza | 1.0 to 1.5 percent | 2 to 3 kg loss | LEADER MACE -13 percent | High |
| Ozempic | 1.5 to 2.0 percent | 5 to 7 kg loss | SUSTAIN-6 MACE -26 percent | High |
| Rybelsus | 1.0 to 1.3 percent | 2 to 4 kg loss | PIONEER 6 safety | High |
| Sulfonylurea (glipizide) | 1.0 to 1.5 percent | 1 to 2 kg gain | No CV benefit shown | Low |
| SGLT2 (empagliflozin) | 0.5 to 1.0 percent | 2 to 3 kg loss | EMPA-REG MACE -14 percent | High |
| Insulin (basal) | 1.5 to 3.0 percent | Weight gain | Glycemic control only | Variable |
Combining Victoza with Other Diabetes Drugs
- With metformin. Very common combination — complementary mechanisms.
- With SGLT2 inhibitors. Additive A1C and weight benefits, plus broader CV and kidney protection.
- With sulfonylureas. Reduce sulfonylurea dose by 25 to 50 percent to lower hypoglycemia risk.
- With basal insulin. Often combined; basal insulin dose may need reduction by 10 to 20 percent at Victoza start.
- With other GLP-1 RAs. Not combined. Switching is done under clinician guidance.
- With DPP-4 inhibitors. Not combined — they work on the same hormonal pathway.
What to Expect in the First Few Months
- Week 1 (0.6 mg starter). Mild nausea or appetite reduction may begin. Fasting glucose may show a small drop.
- Weeks 2 to 4 (1.2 mg). First effective dose. Nausea may resurface for several days, then settle. Fasting glucose continues to fall.
- Weeks 5 to 8. Side effects usually minimal. Weight loss of 1 to 2 kg.
- Week 12. First A1C check. If above target and tolerance is good, escalate to 1.8 mg.
- Months 4 to 6. Maintenance phase. Steady-state A1C and weight effects.
Pediatric Use
Victoza is FDA-approved for children 10 and older with type 2 diabetes — the only injectable GLP-1 RA with this approval. Clinical trial data in this age group showed similar A1C reductions to adults with comparable safety. Dosing is the same: 0.6 mg start, escalating to 1.2 or 1.8 mg daily.
Cost and Insurance
List price for Victoza is about $850 per month, somewhat lower than newer agents like Ozempic or Rybelsus. Most commercial insurance plans cover Victoza for type 2 diabetes with prior authorization. Medicare Part D coverage is widespread. Novo Nordisk offers a savings card for eligible commercially insured patients. Cash discount cards (GoodRx, SingleCare) lower the price by $50 to $200 depending on pharmacy.
Related Reading
For more on this medication and related options, see our pages on Victoza versus Ozempic, Saxenda versus Victoza (the same molecule at different doses), the GLP-1 drug class overview, and our treatment hub. For broader context, see our A1C levels guide. The cardiovascular outcomes are summarized in the ADA Standards of Care 2024.
The Bottom Line
Victoza is a well-established daily GLP-1 receptor agonist for type 2 diabetes that lowers A1C by 1.0 to 1.5 percent, produces 2 to 3 kg of weight loss, and demonstrated a 13 percent reduction in major adverse cardiovascular events in adults with type 2 diabetes and established CV disease (LEADER trial). It is the only injectable GLP-1 RA approved for use in children 10 years and older with type 2 diabetes. Side effects are mostly gastrointestinal and peak during dose escalation. Talk to your clinician about whether Victoza fits your A1C goals, cardiovascular risk profile, and dosing preferences.
